newsfilter
← Latest News
Business Wire·

AgeX Therapeutics' Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001

ImStem's MSC Product Candidate IMS001 is Derived from AgeX's Pluripotent Stem Cell Line ESI-053 AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced to